Other tumors lack both AR expression and neuroendocrine differentiation, and they are called ‘‘double-negative’’ PCa (DNPC), identified in approximately 25% of metastatic CRPC patients [11]. The gene discussed is AR; the disease is posterior cortical atrophy.